Separately, Robert W. Baird assumed coverage on Cue Biopharma in a report on Thursday, July 25th. They set an “outperform” rating and a $13.00 target price on the stock.
NASDAQ CUE traded down $0.02 during mid-day trading on Thursday, reaching $8.17. 76,913 shares of the company’s stock traded hands, compared to its average volume of 122,646. Cue Biopharma has a 1-year low of $4.16 and a 1-year high of $9.94. The firm’s fifty day simple moving average is $7.68. The company has a current ratio of 3.02, a quick ratio of 3.02 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $172.71 million, a P/E ratio of -4.21 and a beta of 1.21.
In other news, SVP Colin Sandercock bought 16,938 shares of Cue Biopharma stock in a transaction on Monday, June 10th. The shares were bought at an average price of $7.83 per share, with a total value of $132,624.54. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have acquired 21,315 shares of company stock worth $163,322. 16.80% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in CUE. Sigma Planning Corp bought a new stake in shares of Cue Biopharma in the 1st quarter worth approximately $325,000. Geode Capital Management LLC raised its stake in Cue Biopharma by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 130,961 shares of the company’s stock valued at $615,000 after acquiring an additional 14,923 shares in the last quarter. Strs Ohio raised its stake in Cue Biopharma by 500.0% during the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock valued at $134,000 after acquiring an additional 12,500 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Cue Biopharma by 16.3% during the 4th quarter. Bank of New York Mellon Corp now owns 51,776 shares of the company’s stock valued at $243,000 after acquiring an additional 7,272 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Cue Biopharma by 1,159.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock valued at $29,000 after acquiring an additional 3,503 shares in the last quarter. 16.62% of the stock is currently owned by institutional investors and hedge funds.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Recommended Story: Conference Calls and Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.